Physician profile
James Parkhurst
NPI 1437193109
$3,751.97
in general payments reported to CMS, 2019-2025
26 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $507 · 2021: $558 · 2022: $111 · 2023: $199 · 2024: $495 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,102.89 | 2019-2025 | |
| Amgen INC. | $527.33 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $311.10 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.73 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $206.38 | 2019-2024 | |
| Amarin Pharma, INC. | $194.74 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $141.00 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.82 | 2019-2020 | |
| Baxter Healthcare | $91.13 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Boston Scientific Corporation | $89.43 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $89.13 | 2021-2025 | Verquvo |
| Innovation Technologies INC | $87.31 | 2025 | Irrisept |
| Pfizer INC. | $86.72 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $66.96 | 2019-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $65.44 | 2021-2024 | Cardiomems |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $51.03 | 2019-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $46.71 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $36.47 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Glaxosmithkline, LLC. | $35.44 | 2025 | Shingrix |
| Abiomed | $30.55 | 2025 | |
| Gilead Sciences, INC. | $25.36 | 2019 | |
| Lundbeck LLC | $20.56 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.84 | 2024 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $18.32 | 2024 | |
| Philips North America LLC | $15.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Parkhurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.